Skip to main content
. 2021 May 20;11:621346. doi: 10.3389/fonc.2021.621346

Figure 5.

Figure 5

The effects EGFR/Akt inhibition on cell proliferation and signaling protein expression. HCT116 cells were treated with 20 μM gefitinib, 20 μM LY294002, and 100 μg/mL SAE for 24 h. (A) Cell viability was measured by WST-1 assays. Statistical analyses were performed using t-tests; *p < 0.05, **p < 0.01, ***p < 0.001. (each experiment, n = 3). N., Negative control; S., SAE; G., Gefitinib; L., LY294002. (B) The cells were treated with 20 μM gefitinib, 20 μM LY294002, and 100 μg/mL SAE for 24 h. The expressions of p-EGFR, p-caveolin, P-Src, p-Akt, p53, Bcl-2, Bak, PARP, and cleaved PARP. Pro-caspase 3, cleaved-caspase 3, and β-actin were analyzed by Western blotting (each experiment, n=3). All western blotting images were quantitatively represented using ImageJ (National Institutes of Health). Statistical analyses were performed using t-tests; *P < 0.05, **P < 0.01, ***p < 0.001 compared to N groups (each experiment, n= 3). The error bars represent the standard error. N., Negative control; S., SAE; G., Gefitinib; L., LY294002.